Scripps Tumorgraft Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Laura Goetz, M.D., Scripps Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01726699
First received: November 6, 2012
Last updated: September 15, 2014
Last verified: September 2014
  Purpose

Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.


Condition
Solid Tumor Malignancy or Hematologic Malignancy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Scripps Tumorgraft Study

Resource links provided by NLM:


Further study details as provided by Scripps Translational Science Institute:

Primary Outcome Measures:
  • Facilitate the development of individualized tumorgraft models for many different types of cancer. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood and tissue samples


Enrollment: 11
Study Start Date: November 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Cancer Diagnosis

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adults with a solid tumor malignancy or a hematologic malignancy

Criteria

Inclusion Criteria:

  • Age 21 or over
  • diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy
  • cognitively and emotionally able to give informed consent

Exclusion Criteria:

  • Under age 21
  • Not cognitively or emotionally able to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01726699

Locations
United States, California
Scripps Translational Science Institute
La Jolla, California, United States, 92037
Sponsors and Collaborators
Scripps Translational Science Institute
Investigators
Principal Investigator: Laura Goetz, MD Director, Applied Genetic Epidemiology
  More Information

No publications provided

Responsible Party: Laura Goetz, M.D., Director, Applied Genetic Epidemiology, Scripps Translational Science Institute
ClinicalTrials.gov Identifier: NCT01726699     History of Changes
Other Study ID Numbers: 12-6011
Study First Received: November 6, 2012
Last Updated: September 15, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on October 16, 2014